Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NewLink’s HyperAcute Program In Limbo After Pancreatic Trial Blow-Up

Executive Summary

Company says it is evaluating what to do with its HyperAcute vaccine candidates in various tumor types, as focus shifts toward IDO programs.

You may also be interested in...

Biomarkers For Pancreatic Cancer To Be Tested In Multi-drug Collaborative Study

Patient advocacy group is spearheading the genomics-driven trial, which will assess if stratification may finally be possible in pancreatic cancer.

Abraxane Drives Growth In Potential $1bn Pancreatic Cancer Market

The year-on-year growth rate of pancreatic cancer drug sales will be around 10% until peaking at around $1bn in 2023. The growth will be driven primarily by strong uptake of Celgene's Abraxane (nab-paclitaxel albumin bond) for the treatment of advanced pancreatic cancer, according to a recent forecast by Datamonitor Healthcare.

Rare Disease Roundtable: Dealing With Pricing Pressure

Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts